Status:
COMPLETED
Gap Junction Potentiation of Endothelial Function With Rotigaptide
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
Chief Scientist Office of the Scottish Government
NHS Lothian
Conditions:
Vascular Disease
Heart Disease
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
Hypothesis - Rotigaptide will improve endothelial function in the context of endothelial dysfunction. The lining of blood vessels (endothelium) can react to hormones in the blood stream causing the b...
Detailed Description
BACKGROUND The endothelium plays a pivotal role in the control of vascular tone and is responsible for the local release of profibrinolytic factors. Nitric oxide (NO), the original endothelium-derived...
Eligibility Criteria
Inclusion
- Healthy volunteers aged between 18-64 years.
Exclusion
- Lack of informed consent
- Age \<18 or \>64 years
- Current involvement in a clinical trial
- Clinically significant comorbidity: heart failure, hypertension, known hyperlipidaemia, diabetes mellitus, asthma, coagulopathy or bleeding disorders\*
- Smoker\*
- Current intake of aspirin, other non steroid anti inflammatory medications or vasodilators\*
- Recent infective/inflammatory condition\*
- Women of child bearing age
- Recent blood donation (preceding three months) \*All cause confounding effects on vascular/endothelial function.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00901563
Start Date
March 1 2009
End Date
August 3 2015
Last Update
June 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc
Edinburgh, United Kingdom, EH16 4SA